GH Research PLC (NASDAQ:GHRS – Free Report) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of GH Research in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $0.10 per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share.
Separately, Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.
GH Research Trading Down 0.7 %
NASDAQ GHRS opened at $9.43 on Tuesday. The business’s 50 day moving average is $8.38 and its two-hundred day moving average is $8.92. GH Research has a 12-month low of $6.00 and a 12-month high of $14.99. The stock has a market capitalization of $490.64 million, a price-to-earnings ratio of -11.94 and a beta of 0.84.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its position in GH Research PLC (NASDAQ:GHRS – Free Report) by 1.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is currently owned by institutional investors and hedge funds.
About GH Research
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
- Five stocks we like better than GH Research
- 3 Small Caps With Big Return Potential
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Best Aerospace Stocks Investing
- 3 Steel Stocks Soaring After Tariff Announcements
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.